This site is intended for healthcare professionals
Search

Find disease awareness content and relevant supporting materials

Learning Zone 327 Events 30 News 17136 Drugs 62278 Trials 8138 Guidelines 837 Journals 3403
Filter results
Sort by:
Relevance
to
Clinical trials
Clinical trial
01/10/09

Dapagliflozin DPPIV Inhibitor add-on Study

This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to...

  • 1 min read
  • Source: Clinicaltrials.gov
Latest drug news
Drug news
14/06/17

Ongoing CVD-REAL trial of Farxiga (dapagliflozin) shows no new safety signals in type 2 diabetes- AstraZeneca

AstraZeneca presented new data underpinning the safety profile of Farxiga (dapagliflozin) with an analysis of data pooled from dapagliflozin clinical...

  • 1 min read
Clinical trials
Clinical trial
30/04/13

DECLARE Dapagliflozin Effect on CardiovascuLAR Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic St

The primary efficacy objective is to determine whether treatment with dapagliflozin compared with placebo when added to current background therapy...

  • 1 min read
  • Source: ClinicalTrialsRegister.eu
Clinical trials
Clinical trial
06/08/14

Dapagliflozin in Type 1 Diabetes (DapaT1DM)

Dapagliflozin is a highly selective, reversible and potent inhibitor of the sodium-glucose-linked Transporter 2 (SGLT2), which was successfully investigated for...

  • 1 min read
  • Source: Clinicaltrials.gov
Latest drug news
Drug news
27/07/13

BMS/AstraZeneca re-file dapagliflozin at FDA

AstraZeneca and Bristol-Myers Squibb Company announced that the FDA has acknowledged receipt of the New Drug Application (NDA) resubmission for...

  • 1 min read
Journals
Journal
15/07/21

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

In the Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in CKD patients with or without type 2 diabetes

  • 1 min read
  • Source: Journal of the American Society of Nephrology
Clinical trials
Clinical trial
15/10/14

Efficacy and Safety Study of Dapagliflozin in Type 1 Diabetes

The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to...

  • 1 min read
  • Source: Clinicaltrials.gov
Clinical trials
Clinical trial
01/12/14

Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight (Dapalost)

Obesity is a medical condition which increases the risk of other diseases, such as type 2 diabetes and cardiovascular disease....

  • 2 min read
  • Source: Clinicaltrials.gov
Clinical trials
Clinical trial
11/10/12

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy with Dapagliflozin added to Saxagliptin in Combination with Metformin compared to Therapy with Placebo added to Saxag

The purpose of this study is to learn if BMS-512148 (dapagliflozin) as part of a triple combination therapy can improve...

  • 1 min read
  • Source: ClinicalTrialsRegister.eu
Clinical trials
Clinical trial
04/11/14

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on

A combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin...

  • 1 min read
  • Source: Clinicaltrials.gov
See more